^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FRAME-001

    i
    Other names: FRAME-001
    Associations

    News

    Trials
    Company:
    CureVac
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2years
    Development of whole Framome personalized cancer vaccines (CIMT 2022)
    Mouse immunogenicity studies with synthetic long peptides showed that Frame neoantigens are immunogenic and induce both CD8+ and CD4+ T cell responses. We have designed and received authorities approval for the first clinical trial with personalized FRAME-001 peptide cancer vaccine for patients with advanced non-small cell lung cancer with unsatisfactory response to the immune checkpoint inhibition.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    FRAME-001
    almost3years
    FRAME-001 Personalized Vaccine in NSCLC (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Frame Pharmaceuticals B.V.
    New P2 trial
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    |
    Keytruda (pembrolizumab) • FRAME-001